Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 24, 2007

View Archived Issues

BKCa channel inhibition attenuates NO-induced dural and pial vasodilation in rats

Newly formed Proaegis Biosciences to develop drugs for ARDS and UC

Preclinical toxicology program for DTS-108 initiated at Diatos

FDA advisory committee recommends use of phosphate binders for hyperphosphatemia treatment

EMEA grants orphan medicinal product designation to picoplatin for SCLC

Phase III trial with Prochymal as first-line treatment for acute GVHD begins

bioMerieux receives FDA clearance for sepsis biomarker assay

Second phase II trial of ADL-5859 initiated for treatment of pain

Lilly and MacroGenics to develop teplizumab for autoimmune diseases

Phase IIa clinical study of MediciNova's MN-305 fails to achieve statistical significance

Complete phase Ib trial of brostallicin combination therapy in advanced solid tumors begins

Analysis reveals safe metabolic profile of bifeprunox

Aripiprazole effective as acute and maintenance therapy for bipolar disorder

RGH-188 pharmacokinetics, dopamine receptor occupancy studied in volunteers

LX-1031 well tolerated in early studies in humans

Novel agents for respiratory and allergic disorders disclosed in recent patent literature

Update on phase II and III studies of thrombin receptor antagonist

New treatment options for neurological disorders reported in recent patent literature

New calcium-activated potassium channel blockers emerge from Merck & Co. R&D

ASIC1a channels, key mediators of inflammatory pain hypersensitivity

GlaxoSmithKline receives approval for ArranonG in T-ALL and T-LBL

Acute heart failure approved as new indication for Sigmart Injection in Japan

Medtronic's drug-eluting stent receives CE Mark

DOR BioPharma receives FDA not approvable letter for orBec in GI GVHD indication

Johnson & Johnson reports third-quarter 2007 results

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...